HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

Fountzilas, George; Valavanis, Christos; Kotoula, Vassiliki; Eleftheraki, Anastasia G; Kalogeras, Konstantine T; Tzaida, Olympia; Batistatou, Anna; Kronenwett, Ralf; Wirtz, Ralph M; Bobos, Mattheos; Timotheadou, Eleni; Soupos, Nikolaos; Pentheroudakis, George; Gogas, Helen; Vlachodimitropoulos, Dimitrios; Polychronidou, Genovefa; Aravantinos, Gerasimos; Koutras, Angelos; Christodoulou, Christos; Pectasides, Dimitrios; Arapantoni, Petroula

doi:10.1186/1479-5876-10-10

Table 2 Selective patient and tumor characteristics

From: HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy

	E-T-CMF		E-CMF		Analyzed cohort
	(N = 159)		(N = 193)		(N = 352)
	Median	Range	Median	Range	Median	Range
Age (in years)	50.2	23.8-75.9	50.6	22.5-78.0	50.6	22.5-78.0
Number of nodes removed	19	5-59	19	4-53	19	4-59
Number of positive nodes	7	0-54	6	0-49	6	0-54
	N	%	N	%	N	%
Nodal involvement (n = 352)
0-3 nodes	34	21.4	54	28.0	88	25.0
≥ 4 nodes	125	78.6	139	72.0	264	75.0
Menopausal status (n = 352)
Premenopausal	83	52.2	104	53.9	187	53.1
Postmenopausal	76	47.8	89	46.1	165	46.9
Type of operation (n = 352)
Modified radical mastectomy	122	76.7	151	78.2	273	77.6
Breast conserving surgery	37	23.3	42	21.8	79	22.4
Interval from operation (n = 352)
< 2 weeks	19	11.9	26	13.5	45	12.8
2-4 weeks	81	50.9	84	43.5	165	46.9
> 4 weeks	59	37.1	83	43.0	142	40.3
*Tumor grade (n = 351)**
I-II	64	40.5	112	58.0	176	50.1
III-Undifferentiated	94	59.5	81	42.0	175	49.9
Tumor size (n = 352)
< 2 cm	45	28.3	67	34.7	112	31.8
2-5 cm	88	55.3	91	47.2	179	50.9
> 5 cm	26	16.4	35	18.1	61	17.3
Adjuvant RT (n = 350)
No	27	17.1	39	20.3	66	18.9
Yes	131	82.9	153	79.7	284	81.1
Adjuvant HT (n = 351)
No	12	7.6	21	10.9	33	9.4
Yes	146	92.4	172	89.1	318	90.6
ER protein status (n = 306)
Negative	40	28.2	41	25.0	81	26.5
Positive	102	71.8	123	75.0	225	73.5
PgR protein status (n = 305)
Negative	52	36.6	54	33.1	106	34.8
Positive	90	63.4	109	66.9	199	65.2
Hormone receptor status (n = 307)
Negative	36	25.4	29	17.6	65	21.2
Positive	106	74.6	136	82.4	242	78.8
Ki67 (n = 309)
Low (< 14%)	25	17.4	30	18.2	55	17.8
High (≥ 14%)	119	82.6	135	81.8	254	82.2
HER2 CISH amplification (n = 285)
Non-amplified	100	75.2	121	79.6	221	77.5
Amplified	33	24.8	31	20.4	64	22.5
HER2 mRNA expression (n = 314)
Low (< 75^th percentile)	108	75.0	128	75.3	236	75.2
High (≥ 75^th percentile)	36	25.0	42	24.7	78	24.8
HER2 protein expression (n = 297)**
0-1+	86	63.2	125	77.6	211	71.0
2+	19	14.0	15	9.3	34	11.4
3+	31	22.8	21	13.0	52	17.5
TOP2A CISH amplification (n = 266)
Non-amplified	110	90.9	137	94.5	247	92.9
Amplified	11	9.1	8	5.5	19	7.1
TOP2A mRNA expression (n = 314)
Low (< median)	72	50.0	85	50.0	157	50.0
High (≥ median)	72	50.0	85	50.0	157	50.0
TopoIIa protein status (n = 273)
Negative	43	35.2	56	37.1	99	36.3
Positive	79	64.8	95	62.9	174	63.7

*: p = 0.001; **: p = 0.023; The distribution of grade and HER2 protein expression differs significantly between the two groups.
RT. radiotherapy; HT. hormonotherapy; CISH. chromogenic in situ hybridization.

Back to article page

ISSN: 1479-5876

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: journalsubmissions@springernature.com

Journal of Translational Medicine

Contact us